EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review

Francisco Javier Gómez Ballesta, Mariel Cecilia Paternina Álvarez, Ana Isabel Betancourt Benítez, María José Montiel Salas, Sergio Armando López Bermúdez, Juan Pablo Alzate Granados

Dermatology Online Journal · 09.05.2026 · 32 (2)

DOI: 10.25251/52gar039 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Francisco Javier Gómez Ballesta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Universidad Autónoma de Bucaramanga, Colombia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Immunomodulating Agents, Immunologic Factors. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Refractory cutaneous lupus (RCL) remains challenging to treat, with limited response to standard therapies. Emerging immunomodulatory agents, including thalidomide, lenalidomide, anifrolumab, belimumab, and intravenous immunoglobulin, may offer improved outcomes.

Methods

A systematic review was conducted following PRISMA guidelines. Randomized controlled trials evaluating the efficacy and safety of the specified agents in adults with RCL were included. Databases searched included MEDLINE, Embase, and LILACS. Primary outcomes were CLASI, BICLA, and SRI‑4 response rates. Secondary outcomes included adverse events and quality of life.

Results

Anifrolumab achieved CLASI‑50 in up to 63.0% of patients versus 30.8% with placebo and BICLA response in up to 53.5% versus 25.7%. Belimumab improved SRI‑4 response to 43.2% versus 33.5% with placebo. RSLV‑132 and tofacitinib demonstrated partial efficacy. Herpes zoster was more frequent with anifrolumab.

Conclusion

Anifrolumab and belimumab provide superior efficacy with acceptable safety in RCL, supporting their inclusion in personalized treatment algorithms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, CutaneousImmunomodulating AgentsImmunologic FactorsHumansAntibodies, Monoclonal, HumanizedThalidomideRandomized Controlled Trials as TopicLenalidomidePiperidinesImmunoglobulins, IntravenousPyrrolesTreatment OutcomePyrimidines

Stichwörter der Autor:innen

anifrolumabbelimumabcutaneousimmunomodulationlupus erythematosusrefractory disease

Substanzen

Antibodies, Monoclonal, HumanizedbelimumabThalidomideanifrolumabImmunomodulating AgentsLenalidomidePiperidinesImmunoglobulins, IntravenoustofacitinibImmunologic Factors

Autor:innen und Institutionen

  • Department of Epidemiology, Universidad Autónoma de Bucaramanga, Colombia.
  • Faculty of Medicine, Universidad de Sucre, Bogotá D.C., Colombia.
  • Faculty of Medicine, Unidad Central del Valle del Cauca (UCEVA), Tuluá, Valle del Cauca, Colombia.
  • Faculty of Medicine, Universidad Juan N. Corpas, Bogotá DC, Colombia.
  • Faculty of Medicine, Universidad Nacional de Colombia, Bogotá DC, Colombia.

Zitieren

APA

Gómez Ballesta, F. J., Paternina Álvarez, M. C., Betancourt Benítez, A. I., Montiel Salas, M. J., López Bermúdez, S. A., & Alzate Granados, J. P. (2026). Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review. Dermatology Online Journal, 32(2). https://doi.org/10.25251/52gar039

Vancouver

Gómez Ballesta FJ, Paternina Álvarez MC, Betancourt Benítez AI, Montiel Salas MJ, López Bermúdez SA, Alzate Granados JP. Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review. Dermatology Online Journal. 2026;32(2). doi:10.25251/52gar039

BibTeX
@article{GmezBallesta2026,
  author = {Gómez Ballesta, Francisco Javier and Paternina Álvarez, Mariel Cecilia and Betancourt Benítez, Ana Isabel and Montiel Salas, María José and López Bermúdez, Sergio Armando and Alzate Granados, Juan Pablo},
  title = {Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review},
  journal = {Dermatology Online Journal},
  year = {2026},
  volume = {32},
  number = {2},
  doi = {10.25251/52gar039}
}
Kostenlos starten →